A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 983 participants.
Also called NCT01649297
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 983 participants
- Registry
-
NCT01649297 -
2012-000905-53
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01649297. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2015-07-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- empagliflozin (low dose qd)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Empagliflozin (high dose qd)
- Intervention (Drug)
- empagliflozin (high dose bid)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- empagliflozin (low dose bid)
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01649297- Content hash
3854a1f91d1c99a2a762443c5e92357e245c07f4b037d1c3edd324385641071b